Genuine Parts Company Announces 66th Consecutive Year of Increased Dividends
2022 Dividend Increases 10%
Get Alerts GPC Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3.1%
Revenue Growth %: +3.7%
Join SI Premium – FREE
ATLANTA, Feb. 14, 2022 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC) announced today a 10% increase in the regular quarterly cash dividend for 2022. The Board of Directors of the Company, at its February 14, 2022 Board meeting, increased the cash dividend payable to an annual rate of $3.58 per share compared with the previous dividend of $3.26 per share. The quarterly cash dividend of eighty-nine and one-half cents ($0.895) per share is payable April 1, 2022 to shareholders of record March 4, 2022. GPC has paid a cash dividend every year since going public in 1948, and 2022 marks the 66th consecutive year of increased dividends paid to shareholders.
About Genuine Parts CompanyFounded in 1928, Genuine Parts Company is a global service organization engaged in the distribution of automotive and industrial replacement parts. The Company's Automotive Parts Group distributes automotive replacement parts in the U.S., Canada, Mexico, Australasia, France, the United Kingdom, Ireland, Germany, Poland, the Netherlands and Belgium. The Company's Industrial Parts Group distributes industrial replacement parts in the U.S., Canada, Mexico and Australasia. In total, the Company serves its global customers from an extensive network of more than 10,000 locations in 15 countries. Genuine Parts Company had 2020 revenues of $16.5 billion. Further information is available at www.genpt.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/genuine-parts-company-announces-66th-consecutive-year-of-increased-dividends-301481465.html
SOURCE Genuine Parts Company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insurance Agent Nick Hogan Explains What First-Time Homeowners Often Miss About Homeowners Insurance in HelloNation
- Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer
- Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share